Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$234.62
-2.4%
$238.68
$229.40
$287.32
$67.78B0.451.41 million shs1.72 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$72.86
+1.2%
$68.30
$48.35
$74.39
$108.05B0.776.66 million shs7.45 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$128.37
+1.4%
$132.11
$74.75
$142.00
$51.05B1.233.03 million shs1.78 million shs
ResMed Inc. stock logo
RMD
ResMed
$216.98
-0.5%
$189.86
$132.24
$237.26
$31.88B0.641.08 million shs640,837 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+2.80%+4.29%-0.28%+1.33%-8.82%
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.25%-1.73%+6.76%+11.93%+36.71%
DexCom, Inc. stock logo
DXCM
DexCom
+0.61%-8.23%-7.32%+4.70%+7.95%
ResMed Inc. stock logo
RMD
ResMed
+1.48%+18.93%+18.32%+13.63%-7.88%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9318 of 5 stars
2.45.03.34.03.72.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.362 of 5 stars
2.53.00.04.22.32.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.957 of 5 stars
3.55.00.04.72.62.53.1
ResMed Inc. stock logo
RMD
ResMed
4.5368 of 5 stars
2.41.03.34.53.21.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0019.34% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
2.95
Moderate Buy$75.093.06% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6710.36% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-6.54% Downside

Current Analyst Ratings

Latest BDX, DXCM, BSX, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$70.00 ➝ $78.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$79.00 ➝ $85.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$72.00 ➝ $82.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$63.00 ➝ $73.00
4/25/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$78.00 ➝ $82.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.50$20.30 per share11.56$88.92 per share2.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
$14.71B7.43$2.93 per share24.87$13.33 per share5.47
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.09$2.11 per share60.83$5.65 per share22.72
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.55$7.88 per share27.53$31.52 per share6.88

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2255.6016.381.936.44%13.57%6.56%8/1/2024 (Estimated)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.1961.2327.812.4812.06%16.63%9.24%7/25/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.5582.8257.312.1516.82%31.01%10.29%7/25/2024 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5133.3325.502.6720.91%24.43%15.70%8/1/2024 (Estimated)

Latest BDX, DXCM, BSX, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q2 24
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.97$3.17+$0.20$4.49$5.04 billion$5.05 billion      
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million    
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.62%+4.77%90.05%52 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.88%+5.66%29.49%12 Years

Latest BDX, DXCM, BSX, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$0.951.62%6/10/20246/10/20246/28/2024
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.32
0.82
DexCom, Inc. stock logo
DXCM
DexCom
1.08
2.90
2.53
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
ResMed Inc. stock logo
RMD
ResMed
1.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.50 billion1.49 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600397.68 million396.05 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable

BDX, DXCM, BSX, and RMD Headlines

SourceHeadline
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
zacks.com - May 3 at 9:46 AM
ResMed Third Quarter 2024 Earnings: Beats ExpectationsResMed Third Quarter 2024 Earnings: Beats Expectations
finance.yahoo.com - May 1 at 9:22 AM
ResMed Inc. (NYSE:RMD) Director Karen Drexler Sells 425 Shares of StockResMed Inc. (NYSE:RMD) Director Karen Drexler Sells 425 Shares of Stock
americanbankingnews.com - May 1 at 5:14 AM
ResMed Inc. (NYSE:RMD) Director Karen Drexler Sells 425 SharesResMed Inc. (NYSE:RMD) Director Karen Drexler Sells 425 Shares
insidertrades.com - May 1 at 5:00 AM
Sivik Global Healthcare LLC Buys New Position in ResMed Inc. (NYSE:RMD)Sivik Global Healthcare LLC Buys New Position in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 30 at 9:13 PM
Insider Selling: ResMed Inc. (NYSE:RMD) Director Sells 425 Shares of StockInsider Selling: ResMed Inc. (NYSE:RMD) Director Sells 425 Shares of Stock
marketbeat.com - April 30 at 4:35 PM
Why ResMed (RMD) is a Top Momentum Stock for the Long-TermWhy ResMed (RMD) is a Top Momentum Stock for the Long-Term
zacks.com - April 30 at 10:56 AM
ResMed Triumphs in Q3 With Strong EarningsResMed Triumphs in Q3 With Strong Earnings
fool.com - April 30 at 10:50 AM
(RMD) - Analyzing ResMeds Short Interest(RMD) - Analyzing ResMed's Short Interest
benzinga.com - April 30 at 10:50 AM
ResMed (NYSE:RMD) Trading Down 3% Following Analyst DowngradeResMed (NYSE:RMD) Trading Down 3% Following Analyst Downgrade
americanbankingnews.com - April 30 at 1:16 AM
Top Stocks to Buy with Rising EPS Estimates After EarningsTop Stocks to Buy with Rising EPS Estimates After Earnings
zacks.com - April 29 at 6:21 PM
Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid ChoiceLooking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid Choice
zacks.com - April 29 at 1:47 PM
ResMed (NYSE:RMD)  Shares Down 3%  After Analyst DowngradeResMed (NYSE:RMD) Shares Down 3% After Analyst Downgrade
marketbeat.com - April 29 at 10:59 AM
Heres Why ResMed (RMD) is a Strong Growth StockHere's Why ResMed (RMD) is a Strong Growth Stock
zacks.com - April 29 at 10:46 AM
ResMed (NYSE:RMD) Price Target Raised to $238.00ResMed (NYSE:RMD) Price Target Raised to $238.00
americanbankingnews.com - April 29 at 5:20 AM
Needham & Company LLC Boosts ResMed (NYSE:RMD) Price Target to $236.00Needham & Company LLC Boosts ResMed (NYSE:RMD) Price Target to $236.00
americanbankingnews.com - April 29 at 5:20 AM
Why is the ResMed share price surging again and up 14% in two sessions?Why is the ResMed share price surging again and up 14% in two sessions?
msn.com - April 28 at 10:28 PM
ResMed Silences The DoubtersResMed Silences The Doubters
fnarena.com - April 28 at 10:28 PM
ResMed shares hit 10-month highs on earnings beat, weight-loss drug tailwindsResMed shares hit 10-month highs on earnings beat, weight-loss drug tailwinds
marketindex.com.au - April 28 at 10:28 PM
ResMed (NYSE:RMD) PT Raised to $200.00 at Royal Bank of CanadaResMed (NYSE:RMD) PT Raised to $200.00 at Royal Bank of Canada
americanbankingnews.com - April 28 at 5:56 AM
ResMed (NYSE:RMD) PT Lowered to $200.00ResMed (NYSE:RMD) PT Lowered to $200.00
americanbankingnews.com - April 28 at 5:20 AM
ResMed Inc. (RMD) Q3 2024 Earnings Call TranscriptResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
seekingalpha.com - April 27 at 9:19 PM
ResMed Inc. (NYSE:RMD) Stake Increased by C WorldWide Group Holding A SResMed Inc. (NYSE:RMD) Stake Increased by C WorldWide Group Holding A S
marketbeat.com - April 27 at 5:21 PM
ResMed Inc. Announces Quarterly Dividend of $0.48 (NYSE:RMD)ResMed Inc. Announces Quarterly Dividend of $0.48 (NYSE:RMD)
marketbeat.com - April 27 at 10:47 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.